Tvardi Therapeutics closed at $0.86 on Nov 4, up 3.17%, 82.8% below its 52-week closing high. Volume of 50.0K shares was 0.41× its 20-day average (below normal).
Split-adjusted performance: -20.2% over one month, -76.5% over six months, -80.9% over one year.
Short interest was 375.9K shares at the Oct 15 settlement, up 67.5% from the prior report (6.9% of float, 2.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TVRDTvardi Therapeutics | $0.8614 | +3.17% | −76.5% | — | — | — | $11.5M | |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
| CLRBCellectar Biosciences INC NEW | $1.23 | −6.11% | −65.2% | — | — | — | $11.6M | Compare |
| BIVIBioVie | $1.34 | −22.54% | −19.3% | — | — | — | $11.6M | Compare |
| LPCNLipocine | $1.44 | −1.37% | −40.7% | −100.0% | — | — | $11.9M | Compare |
| RKTORocket One | $0.4422 | −4.33% | — | — | — | — | $11.0M | Compare |
| HINDVyome Holdings | $1.74 | −1.93% | −21.1% | — | −2543.3% | — | $12.2M | Compare |
| PTNPalatin Technologies | $6.02 | +15.33% | −68.3% | — | −1449.1% | — | $10.7M | Compare |
| AEONAEON Biopharma | $0.2086 | −1.70% | −77.0% | — | — | — | $12.3M | Compare |
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
